Insider Selling: ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells 12,000 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vivek Jain also recently made the following trade(s):

• On Tuesday, September 3rd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00.
• On Friday, August 16th, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00.

ICU Medical Price Performance

Shares of ICUI traded down $3.08 during mid-day trading on Tuesday, hitting $179.14. 671,249 shares of the company were exchanged, compared to its average volume of 283,689. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of -72.49 and a beta of 0.65. ICU Medical, Inc. has a 1-year low of $78.28 and a 1-year high of $188.53. The company has a 50 day moving average of $155.95 and a 200-day moving average of $124.76. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.58 earnings per share. Analysts expect that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

A number of large investors have recently modified their holdings of ICUI. Innealta Capital LLC acquired a new position in ICU Medical during the second quarter worth about $32,000. Motco purchased a new position in ICU Medical in the 1st quarter worth approximately $29,000. GAMMA Investing LLC lifted its stake in ICU Medical by 75.1% in the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 133 shares in the last quarter. EntryPoint Capital LLC boosted its holdings in shares of ICU Medical by 731.5% during the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of ICU Medical by 46.4% in the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ICUI. Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. Finally, KeyCorp boosted their price objective on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $149.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.